TScan Therapeutics, Inc. Share Price & Technical Analysis
TCRX · $1.06 (+3.92%)
Healthcare / Biotechnology
$1.06
+3.92%
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-8% return in May, -2% avg return in past 3 year May month.
22% return in 2026, 28% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 10% | 0% | 20% | -8% | – | – | – | – | – | – | – | 22% |
| 25 | -16% | -16% | -33% | 14% | -12% | 7% | 13% | 6% | 0% | 6% | -27% | -9% | -68% |
| 24 | -14% | 33% | 16% | -4% | 10% | -33% | 20% | -22% | -11% | -8% | 4% | -37% | -45% |
| 23 | 13% | 67% | -25% | 15% | -4% | 14% | -12% | 9% | 8% | 52% | 71% | -11% | 196% |
| 22 | 4% | -12% | -36% | -24% | 52% | -3% | 42% | -33% | 7% | -13% | -21% | -29% | -67% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$72.87M
P/E ratio
—
52W high
$2.57
52W low
$0.88
Volume
6,76,325
Beta
1.06
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is TScan Therapeutics, Inc. share price today?
- TScan Therapeutics, Inc. (TCRX) last traded around $1.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TCRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TCRX. Download the app for real-time alerts.
- How can I analyze TScan Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.